# Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

> **NCT07474064** · PHASE2 · NOT_YET_RECRUITING · sponsor: **chenxu** · enrollment: 146 (estimated)

## Conditions studied

- Muscle Invasive Bladder Cancer (MIBC)

## Interventions

- **DRUG:** Probiotic
- **DRUG:** Disitamab Vedotin
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07474064
- **Lead sponsor:** chenxu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2031-03-31
- **Final completion:** 2035-03-31
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07474064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07474064, "Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07474064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*